GLP-1 Weight Loss Drugs Are Reshaping How We Eat and Drink

Weight loss medicines like GLP-1 drugs are changing how people eat and drink. Nearly all users say these treatments have altered their habits in some way. From cutting back on alcohol to choosing healthier meals, the shift is noticeable across restaurants, pubs, and supermarkets.

About one in eight American adults now takes GLP-1 medications, with Europe also expanding access. In February 2026, the European Commission approved a higher 7.2 mg weekly dose of Wegovy for adults with obesity after trials showed an average weight loss of around 21%.

The impact of these drugs is clear in food and drink choices. Over a quarter of users now pick more nutritious dishes or lower-calorie options when eating out. Many skip starters or desserts, opt for smaller portions, or avoid carbs and fried foods entirely. In takeaway and delivery orders, sales of alcohol, crisps, and sweets have dropped.

Pubs and fast-food restaurants are seeing fewer visits too. A third of users have reduced how often they go to fast-food chains and food pubs, though cafes and coffee shops remain popular. Despite this, 57% of users still eat out at least once a week, and 48% drink out just as often. The trend extends beyond food. Nearly 30% of users are drinking less alcohol or pacing themselves more. At home, households with a GLP-1 user spend about 5% less on everyday groceries. Many are also paying closer attention to health trends, with 35% actively keeping up with wellness developments. Usage is highest among older adults. Over half of users are aged 25 to 44, while 37% are 45 or older. Only 10% are 24 or younger, suggesting the drugs appeal more to middle-aged and older consumers.

The rise of GLP-1 medications is reshaping spending and consumption patterns. Restaurants, supermarkets, and pubs are adjusting as users cut back on certain foods and drinks. With more people taking these drugs, the effects on eating and drinking habits are likely to grow even stronger.